Hematopoietic Support by Adipose-Derived Stromal Cells

脂肪源性基质细胞的造血支持

• 批准号: 6435095
• 负责人: Jeffrey Martin Gimble
• 金额: $ 10万
• 依托单位: ARTECEL SCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-06-18 至 2001-12-17
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6435095
• 关键词: adipose tissue; bone marrow; cell differentiation; cell proliferation; cell sorting; hematopoietic tissue; human tissue; tissue /cell culture

Bone marrow transplantation requires large numbers of pluripotent hematopoietic stem cells to achieve a successful clinical outcome. Therefore, there is a pressing medical need for methods to expand stem cells ex vivo and accelerate their engraftment in vivo. These steps may be supported by cytokine-producing stromal cells. The scientists at Artecel Sciences have developed proprietary techniques to isolate and culture human stromal cells from adipose tissue that can be used for autologous and allogeneic transplantation. This SBIR investigates the hypotheses that adipose derived stromal cells will (1) support hematopoietic progenitor cell proliferation and differentiation in vitro and (2) accelerate their engraftment in vivo. Aim 1 (Phase I) will demonstrate that human adipose derived stromal cells will support proliferation of multipotent and pluripotent hematopoietic progenitors in short and long term cultures using flow cytometric and methylcellulose assays. This work provides a foundation for Phase H studies to determine: (Aim 3) The ability of ex vivo expanded hematopoietic progenitors to repopulate sublethally irradiated NOD/SCID mice; (Aim 4) The ability of adipose derived stromal cells to accelerate hematopoietic stem cell engraftment in sublethally irradiated NOD/SCID mice. PROPOSED COMMERCIAL APPLICATION: This SBIR will develop technology with application to all patients receiving bone marrow transplantation. Each year, 20,000+ patients under this therapy at an individual cost of $100,000. Artecel Sciences technology has the potential to significantly reduce the clinical and financial burden of these procedures.

骨髓移植需要大量的多能造血细胞 干细胞取得成功的临床结果。因此，迫切需要 医学上需要体外扩增干细胞并加速其增殖的方法 体内植入。这些步骤可能得到产生细胞因子的基质的支持 细胞。 Artecel Sciences 的科学家们开发了专有技术 从脂肪组织中分离和培养人类基质细胞，可用于 自体和同种异体移植。该 SBIR 调查了以下假设 脂肪来源的基质细胞将 (1) 支持造血祖细胞 体外增殖和分化；（2）加速它们在体内的植入。 目标 1（第一阶段）将证明人类脂肪来源的基质细胞将 支持多能和多能造血祖细胞的增殖 使用流式细胞仪和甲基纤维素测定进行短期和长期培养。这 工作为 H 期研究奠定了基础，以确定：（目标 3） 离体扩增造血祖细胞以重新繁殖亚致死辐射 NOD/SCID 小鼠； （目标 4）脂肪源性基质细胞加速生长的能力 造血干细胞植入亚致死照射的 NOD/SCID 小鼠中。 拟议的商业应用： 该 SBIR 将开发适用于所有接受骨治疗的患者的技术 骨髓移植。每年，超过 20,000 名患者接受这种疗法 个人费用为100,000美元。 Artecel Sciences 技术有潜力 显着减轻这些手术的临床和财务负担。